Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Ikena Oncology, Inc. Common Stock (IKNA)

Biological Products, (no Disgnostic Substances)

https://www.ikenaoncology.com

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.

50 NORTHERN AVE.
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/26/2021

Market Cap

82,280,061

Shares Outstanding

48,260,000

Weighted SO

48,258,111

Total Employees

N/A

Upcoming Earnings

08/08/2024

Beta

0.4810

Last Div

0.0000

Range

1.02-5.205

Chg

0.0250

Avg Vol

293912

Mkt Cap

82280061

Exch

NASDAQ

Country

US

Phone

857 273 8343

DCF Diff

1.7866

DCF

-0.0766

Div Yield

0.0000

P/S

44.6204

EV Multiple

-0.6581

P/FV

0.5760

Div Yield %

0.0000

P/E

-1.2334

PEG

-0.1081

Payout

0.0000

Current Ratio

18.2188

Quick Ratio

18.2188

Cash Ratio

5.4012

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

598.9744

CCC

-598.9744

Gross Margin

0.5347

Op Margin

-39.1513

Pretax Margin

-36.2153

Net Margin

-36.1757

Eff Tax Rate

0.0047

ROA

-0.4236

ROE

-0.4281

ROCE

-0.4836

NI/EBT

0.9989

EBT/EBIT

0.9250

EBIT/Rev

-39.1513

Debt Ratio

0.0577

D/E

0.0636

LT Debt/Cap

0.0364

Total Debt/Cap

0.0598

Int Coverage

-55.7060

CF/Debt

-7.9875

Equity Multi

1.1024

Rec Turnover

0.0000

Pay Turnover

0.6094

Inv Turnover

0.0000

FA Turnover

0.3322

Asset Turnover

0.0117

OCF/Share

-1.5049

FCF/Share

-1.5103

Cash/Share

3.0134

OCF/Sales

-39.3829

FCF/OCF

1.0036

CF Coverage

-7.9875

ST Coverage

-19.6541

CapEx Coverage

-277.1832

Div&CapEx Cov

-277.1832

P/BV

0.5760

P/B

0.5760

P/S

44.6204

P/E

-1.2334

P/FCF

-1.1289

P/OCF

-1.1330

P/CF

-1.1330

PEG

-0.1081

P/S

44.6204

EV Multiple

-0.6581

P/FV

0.5760

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation